**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 80064

**Manuscript Type:** MINIREVIEWS

**Probiotics for preventing gestational diabetes in overweight or obese pregnant women: A review**

Deng YF *et al*. Probiotics in overweight/obese pregnant women

Ya-Fang Deng, Li-Ping Wu, Yan-Ping Liu

**Ya-Fang Deng, Li-Ping Wu,** Chinese Academy of Medical Sciences and Peking Union Medical College, School of Nursing, Beijing 100730, China

**Yan-Ping Liu,** Department of Clinical Nutrition, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing 100730, China

**Author contributions:** All authors conceptualized the idea of the article; Deng YF contributed to manuscript drafting, organized data, and reviewed the literature; and all authors contributed to revising the paper and approved the final publishing.

**Corresponding author: Yan-Ping Liu, MSN, Occupational Physician,** Department of Clinical Nutrition, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, No. 1, Shuaifuyuan, Dongcheng District, Beijing 100730, China. liuyp1227@vip.sina.com

**Received:** September 17, 2022

**Revised:** November 12, 2022

**Accepted:** December 8, 2022

**Published online:**

**Abstract**

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host. Specific probiotics or probiotic foods can be used to reduce the risk of diseases associated with aberrant gut microbiota composition. The incidence of gestational diabetes mellitus (GDM) has increased annually with the proportion of overweight and obese people. Overweight or obese pregnant women are at high risk of GDM and have obvious changes in gut microbiota compared with normal-weight pregnant women. Specific probiotics or probiotic foods may alter gut microbiota in overweight or obese pregnant women and inhibit the expression of inflammatory factors, consequently resulting in weight loss and reduced insulin resistance. This review discusses the mechanism of probiotics on GDM, as well as the dose, method and duration of probiotics use, and summarizes current evidence on probiotics in improving glucose metabolism and other maternal and infant outcomes in overweight/obese pregnant women.

**Key Words:** Probiotics; Gut microbiota; Diabetes, Gestational; Overweight; Obesity, Maternal

Deng YF, Wu LP, Liu YP. Probiotics for preventing gestational diabetes in overweight or obese pregnant women: A review. *World J Clin Cases* 2022; In press

**Core Tip:** The occurrence and progression of gestational diabetes mellitus (GDM) are associated with intestinal microbiota disorder. Probiotics modulate the gut microbiota, which can decrease lipopolysaccharide-containing microbiota in the gut and plasma lipopolysaccharides, and inhibit expression of inflammatory factors, thereby reducing insulin resistance, modulating glucose metabolism, and preventing GDM, especially in high-risk groups such as overweight/obese pregnant women. This review provides up-to-date evidence on the effects of probiotics in preventing GDM and improving glucose metabolism and other maternal and infant outcomes in overweight/obese pregnant women, and discusses the mechanism of probiotics on GDM, and the dose, method, and duration of probiotics use.

**INTRODUCTION**

Probiotics are defined by the Food and Agriculture Organization of the United Nations/World Health Organization (WHO) as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host[1]. Probiotic supplementation is well tolerated and safe even in pregnant women and their children[2-5]. However, adverse effects such as stomach ache, flatulence, dystocia, amniotic fluid reduction, Crohn’s disease, and headache have been reported[3,6,7]. Gastrointestinal symptoms are the most common adverse effects[3]. An increased risk of pre-eclampsia, including superimposed, has been reported after probiotic administration, in systematic reviews and meta-analyses[8-10]. However, a systematic review and meta-analysis in 2021 indicated that adverse effects associated with probiotic and prebiotic use do not pose any serious health concerns to mothers or infants[2]. As dietary adjuncts, specific probiotics or probiotic foods can be used to reduce the risk of diseases associated with aberrant gut microbiota composition, increased intestinal permeability, or altered immunological or metabolic balance[11].

The human gut microbiota is engaged in multiple interactions affecting host health during the host’s entire lifespan, modulating key processes in metabolism, inﬂammation and immunity[12,13]. Koren *et al*[14] indicated that host-microbial interactions that affect host metabolism can occur and may be beneﬁcial in pregnancy. During pregnancy, the gut microbiota plays a crucial role in metabolic dysfunction[15]. Maternal status is associated with alterations in the compositions and diversity of the intestinal microbiota community during gestation[15]. Maternal metabolic disorders can influence the long-term health of mothers and their offspring[15]. The composition of the gut microbiota is significantly altered in pregnant women with gestational diabetes mellitus (GDM), pre-eclampsia, abnormal placental growth, and obesity compared with healthy pregnant women[15,16]. Scientific probiotic and prebiotic supplements have positive effects on mothers and their offspring.

GDM is the diagnosis of diabetes in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation[17], and is a common complication in pregnant women that can negatively affect pregnancy outcomes and short- and long-term maternal and child health[18]. Pre- or early-pregnancy overweight or obese pregnant women are at high risk of GDM[6,19]. As the proportion of overweight and obese people has increased, the incidence of GDM has also increased annually[20,21]. WHOrecommends the following international body mass index cutoff for adults[22]: Overweight = 25.0-29.9 kg/m2 and obese ≥ 30 kg/m2, but standards vary from country to country. A narrative review indicated that the body weight condition might be the critical factor for the effects of probiotics on GDM[23].

Current research on the use of lifestyle interventions to prevent GDM is contradictory, particularly the efficacy of prevention, which differs among obese pregnant women[24]. Some reviews or meta-analysis[25-27] showed that probiotics may reduce blood glucose level in pregnant women and prevent GDM, especially in high-risk groups including overweight or obese pregnant women[10], excessive weight gain during pregnancy, and abnormal gut microbiota[11]. Therefore, probiotics might be a new strategy for preventing GDM. We review the mechanism of probiotics on GDM, as well as the dose, method, and duration of probiotics administration, and summarize current evidence on probiotics in preventing GDM or improving glucose metabolism and other maternal and infant outcomes in overweight/obese pregnant women.

**MECHENISM OF PROBIOTICS oN PREVENTING GDM IN OVERWEIGHT/OBESE PREGNANT WOMEN**

Intestinal microorganisms perform many important functions; one of which is participation in metabolic processes such as the production of short-chain fatty acids (SCFAs)[28]. SCFAs mediate the transmission of signals between the microbiome and the immune system and are responsible for maintaining balance in the anti-inﬂammatory reaction, such as propionic and n-butyric acids produced in the large intestine by gut bacteria[29]. The level of propionic acid decreases with the course of pregnancy, while obese women have an increased level, which is associated with many metabolic adaptations[29]. Szczuko *et al*[29] showed that propionic and linear caproic acid levels can be critical in maintaining lower anthropometric parameters during pregnancy. Pregnancy stages alter the gut microbiota community structure[29]. Reduced numbers of *Bifidobacterium* and increased numbers of *Staphylococcus*, *Enterobacteriaceae*, and *Escherichia coli* were detected in overweight compared with normal-weight pregnant women[30,31]. Meanwhile, fecal *Bacteroides* and *Staphylococcus* concentrations were significantly higher and bifidobacterial counts were less in infants of overweight mothers during the first 6 mo of life compared with nonobese mothers[13]. Obese (high-fat feeding) can increase lipopolysaccharide-containing microbiota in the gut and plasma leading to a state of chronic low-grade systemic inflammation that is casually linked to insulin resistance (IR)[32,33]. A systematic review by Shirvani-Rad *et al*[34] indicated that the probiotic products could be of beneﬁt to managing obesity when using them as an adjunct therapy at high dose.

The incidence of GDM is obviously associated with changes in the gut microbiota (increased levels of *Enterobacteriaceae* and *Enterococcus* and decreased levels of *Bifidobacteria* and *Lactobacillus*)[11,35,36]. Mokkala *et al*[37] reported that an interaction between GDM status and intervention was observed in women without GDM, which means that the evolution of the gut microbiota throughout pregnancy is influenced by GDM and dietary intervention. Specific gut microbiota species do not differ between women with and without GDM and gut microbiota is neither involved in the incidence of GDM nor differs according to GDM status. Intestinal microbiota disorder during pregnancy may interact with various pathways such as IR, chronic inflammatory reaction, endotoxemia, and energy metabolism[38]. Chronic inﬂammatory reaction increases IR, deceases insulin-like growth factor binding protein (IGFBP), disrupts the function of pancreatic β cells and insulin secretion, which can cause and promote progression of GDM[39]. New means to stabilize the microbial balance during pregnancy could benefit maternal health[40]. Pregnant women may benefit from gut microbiota targeted dietary supplementation[37].

The use of probiotic microorganisms to prevent and treat intestinal dysbiosis, leading to an increase in SCFAs in the colon, seems to be an important direction for further research[28]. Isolauri *et al*[11] showed that probiotics could balance the properties of aberrant endogenous microbiota, and regulate intestinal permeability and the secretion of proinflammatory mediators to control systemic and local inflammatory status and energy efficiency, which could be the underlying mechanisms of probiotics in GDM. Overweight and obese women without GDM, particularly those receiving the fish oil + probiotics combination, manifested changes in relative abundance of bacterial species over the pregnancy in a randomized controlled trial (RCT) in 2021[37]. Halkjær *et al*[41] also found that multistrain probiotics consisting of *Streptococcus thermophilus* DSM 24731*, Bifidobacteria*, and *Lactobacilli* can modulate the gut microbiota and increase α-diversity in obese pregnant women, but a larger study population is needed to determine pregnancy effects after probiotic supplementation. When the abundance of these key species began to decline, a collapse in symbiosis was observed, reflected in a deterioration in host metabolic health[42]. A systematic and meta-analysis of RCTs found that probiotic supplements reduce the level of fasting plasma glucose (FPG) and improve insulin, IR, and insulin sensitivity, especially for GDM and healthy pregnant women[42]. However, for overweight or obese pregnant women, a network meta-analysis in 2019 showed that interventions that aim to prevent GDM, such as physical exercise programs, and administration of metformin, vitamin D, and probiotics are not effective[43]. Therefore, we wondered whether probiotics may modulate the abundance of gut microbiota in overweight/obese pregnant women, which could decrease both the proportion of lipopolysaccharide-containing microbiota in the gut and plasma lipopolysaccharides[11], and they also inhibit the expression of inflammatory factors, thereby reducing IR, modulating glucose metabolism, and preventing GDM.

**SPECIES, DOSE, METHOD, AND DURATION OF PROBIOTICS**

Most of the probiotic properties are species- and strain-specific[11]. The properties of each probiotic strain should be well deﬁned and cannot be extrapolated to other strains[44]. Sánchez *et al*[44] stated that it is necessary to scientiﬁcally demonstrate the efﬁcacy of the strain in conferring a health beneﬁt on the host, but this effect does not have to be linked to any speciﬁc mechanism of action. The most common probiotic species include *Bifidobacterium*, *Lactobacillus paracasei*, *Streptococcus thermophilus* and *Lactobacillus rhamnosus* (*L. rhamnosus*), which are also part of the normal human microbiome[45]. The main probiotics used in studies contained *Bifidobacteria* and *Lactobacilli*. It has been proven that *Bifidobacteria* can encompass degradation of nondigestible carbohydrates, protect against pathogens, produce vitamin B, antioxidants, and conjugate linoleic acids, and stimulate the immune system[46]. Strains of *Lactobacillus*, *Bifidobacterium*, and *Saccharomyces* have a long history of safe and effective use as probiotics, but *Roseburia* *spp.*, *Akkermansia spp.*, *Propionibacterium spp.*, and *Faecalibacterium spp.* show promise for the future[47]. As another dominant genus of intestinal microbiota, *Blautia* plays some part in metabolic diseases, inflammatory diseases, and biotransformation[48]. There is a disparity in association of *Blautia* with human diseases (less in sufferers of diabetes/obesity, but more in inflammatory bowel disease)[48]. Because of the probiotic properties, the effects of different species or strains probiotics should be explored.

The dose, method, and duration of probiotics has varied among studies. The dose may have a major influence on the effect of probiotics administration. A 12-wk RCT in 81 obese postmenopausal women showed that signiﬁcant favorable changes (mostly large or medium effects) in the evaluated parameters, including waist, total cholesterol, low-density lipoprotein, and insulin in the high-dose [1010 colony forming units (CFU)/d] and low-dose (2.5 × 109 CFU/d) groups by receiving lyophilisate powder containing several species of live probiotic bacteria[49]. The high-dose, low-dose, and placebo groups showed signiﬁcant differences in lipopolysaccharide levels, glucose, insulin, and homeostasis model assessment of IR (HOMA-IR)[49]. Using the multispecies probiotic Ecologic® Barrier favorably in a dose-dependent manner can have beneﬁcial effects[49]. The meta-analysis by Zheng *et al*[50] indicated that the dose or CFU of a probiotic is an important factor in the efficacy of probiotic supplementation on metabolic health in pregnant women, and a dose > 107 CFU probiotic counts can show beneficial effects. For overweight/obese pregnant women, the dose of probiotic may be not less than 109 CFU/d[3,6,41,51].

Diet is a principal driver of gut fermentation and therefore can influence functionality of the indigenous microbiota[47]. The combination of dietary probiotics and probiotic supplements might reduce the risk of GDM and larger birth size because of the synergy between a probiotic-rich diet and probiotic supplements[37,52,53]. Luoto *et al*[53] studied the safety and efficacy of perinatal probiotic-supplemented dietary counseling (additionally intensive dietary counseling complying with current recommendations at every study visit provided by a nutritionist, combined with conventional food products with favorable fat and ﬁber contents for use at home) in normal weight pregnant women. The intervention group (probiotics + diet) had a reduced frequency of GDM compared with the diet/placebo and control groups. However, probiotics combined with diet in overweight/obese pregnant women for the prevention of GDM were not investigated in that study. Mokkala *et al*[37] indicated that overweight and obese women without GDM may benefit from dietary modulation through gut microbiota modulation.

Specific probiotics or probiotic foods were mainly administered orally in ice-stored probiotic capsules or probiotic yogurt, and one studyreported that two participants stopped taking the capsules because they were difficult to swallow[41]. Asgharian *et al*[6] showed some beneficial effects on glucose metabolism in overweight and obese pregnant women by using probiotic yogurt, whereas no significant differences were found in other studies provided with probiotic capsules[3,41,51,54,55]. A review reported daily consumption of 200 g yogurt containing *Lactobacillus gasseri* (108 CFU/g) for 12 wk signiﬁcantly reduced abdominal obesity[39]. According to a study by Homayoni *et al*[56], foods are better carriers of probiotics than supplements are. In the study by Lindsay *et al*[55], obese pregnant women were required to take probiotics after meals, which may have reduced the possibility of adverse gastrointestinal symptoms. Other similar studies did not report the specific time of probiotic supplementation. Some researchers recommended the administration of probiotic capsules with a glass of cold water or milk (avoiding acidic or hot drinks), to keep the strain active[7].

The cointervention of multiple alive bacteria strains on preventing and treating metabolic diseases could be a promising method of treatment[23]. Prebiotics are defined in 2017 as “a substrate that is selectively utilized by host microorganisms conferring a health benefit,” which is a popular dietary approach to the modification of the gut microbiota to improve host health[47,57]. Prebiotics such as inulin-type fructans and arabinoxylan oligosaccharides can be consumed to increase the number of *Biﬁdobacteria* and cause butyrogenic effects in the human colon, which are the result of crossfeeding interactions between *Biﬁdobacteria* and butyrate-producing colonic bacteria[46]. Butyrate is an essential metabolite in the human colon, as it is the preferred energy source for the colonic epithelial cells, and contributes to the maintenance of the gut barrier functions, and has immunomodulatory and anti-inﬂammatory properties[46]. Butyrate and propionate regulate glucose metabolism by stimulating the process of intestinal gluconeogenesis[29]. Personalized nutrition and precision medicine are beginning to influence the application of probiotics and prebiotics[58]. Synbiotics are a mixture comprising live microorganisms and substrates selectively utilized by host microorganisms that confers a health benefit on the host, which is better than prebiotics alone[59]. Studiesalso showed that probiotics and prebiotics (synbiotics) were used to modulate the maternal gut microbiome composition, which might enhance probiotic survival and growth better than probiotics alone[39,52]. A narrative review by Li *et al*[23] reported that novel food-processing strategies like enzyme-modiﬁed prebiotics and probiotic-fermented natural foods have been developed to enhance the beneﬁcial effects on alleviating metabolic diseases.

At present, all studies on the use of probiotics in overweight/obese pregnant women start from the second or third trimester of pregnancy. The commencement of probiotics in the first trimester would be important to explore in future research, but Callaway *et al*[51] believes that this poses practical difficulties in routine clinical practice. Xie *et al*[10] showed that longer duration (≥ 8 wk) of probiotics had a more significant preventive effect on GDM. Whether and which species, dose, method, and duration of probiotics administration will affect the prevention of GDM or improve glucose metabolism and maternal and infant outcomes remain to be further explored.

**EFFECTS OF PROBIOTICS ON GLUCOSE METABOLISM IN OVERWEIGHT/OBESE PREGNANT WOMEN**

A few studies have used probiotics in overweight/obese women in the second and third trimester of pregnancy to reduce FPG at 24-28 wk of gestation and the incidence of GDM (the diagnostic criteria for GDM vary among different studies). The results of these studies on FPG are inconsistent, and no significant differences on the incidence of GDM between the groups were observed (Table 1). Lindsay *et al*[55] reported that probiotic capsules (*L. salivarius* UCC118) in obese pregnant women at 24-28 wk gestation do not reduce maternal fasting glucose or the incidence of GDM, and longer administration may be required for any probiotic effect to be exerted. The probiotics [*L. rhamnosus* and *B. animalis* subsp. *lactis* (BB-12)] used in the SPRING prospective double-blind randomized trial also did not prevent GDM in 433 overweight and obese pregnant women, who started taking probiotic capsules from 20 wk gestation to delivery[51]. However, they noted a higher fasting glucose level in the probiotics group. Although they used identical probiotics to Luoto *et al*[53], dietary counseling may have played a key role. However, Asgharian *et al*[6] showed that probiotic yogurt [*Lactobacillus acidophilus* (*L. acidophilus*) La5 and *Bifidobacterium lactis* Bb12, 5 × 1010 CFU/d] provided from 24 wk gestation to delivery decreased FPG and 2 h PG oral glucose tolerance test at 28 wk gestation in overweight and obese women, which may be related to the species of probiotic bacteria and the viable count in probiotic yogurt. Different strains of probiotics (*Lactobacilli* and *Bifidobacteria*)may also affect the results. Halkjær *et al*[41] provided multistrain probiotics that increased the gut microbiota diversity in obese pregnant women, but there was no significant difference in GDM and gestational weight gain (GWG). Further studies in different settings with a larger number of participants are recommended. Pellonperä *et al*[3] reported that fish oil and/or probiotics during pregnancy did not lower the risk of GDM or improve glucose metabolism in 439 overweight and obese women. In high-risk pregnant women, Shahriari *et al*[7] provided probiotic capsules containing a mixture of *L. acidophilus* LA1, *Bifidobacterium longum* sp54 cs, and *Bifidobacterium bifidum* sp9 cs, and the results showed that probiotics supplementation from the first half of the second trimester up to 24 wk of pregnancy did not reduce the risk of GDM. Further studies should focus on the effect of probiotics on the incidence of GDM in high-risk pregnant women.

The effect of probiotics on preventing GDM in overweight or obese pregnant women has been the subject of debate in current systematic reviews and meta-analysis[9,10]. The study by Chu *et al*[9] found that there were no signiﬁcant differences between probiotics and placebo on GDM and suggested that probiotics were not a promising approach to prevent GDM and promote the health of subsequent generations. However, the latest meta-analysiscarried out in China reported that probiotics can effectively prevent GDM in overweight and obese pregnant women[10]. As the number, sample size and quality of studies have been limited, more well-designed large trials are needed for better meta-analyses.

IR during pregnancy is the pathogenetic basis of GDM, and increased levels of microinflammatory factors are one of the main manifestations of IR[18]. Related studiesmeasured HOMA-IR and C-peptide as secondary outcomes[3,55], which increased from early to date pregnancy in all intervention groups, and there were no significant differences between the different groups. From the same RCT as Pellonperä *et al*[3], Houttu *et al*[60] measured high-sensitivity C-reactive protein (hsCRP), matrix metalloproteinase (MMP)-8, phosphorylated insulin-like growth factor binding protein-1 (IGFBP-1), IGFBP-1 and vaginal MMP-8 in the different intervention groups and in all of the overweight/obese pregnant women. IGFBP, which may affect the development of GDM, differed significantly between women with or without GDM. The increased level of microinflammatory factors is one of the main manifestations of IR, which is mainly a chronic inflammatory reaction centered on the release of proinflammatory factors such as interleukin-6 and tumor necrosis factor α[18]. Glycoprotein acetylation (GlycA) is a composite nuclear magnetic resonance biomarker of systemic inflammation, including α1-acid glycoprotein, touchglobin, α1-antitrypsin, α1-antichymotrypsin and transferrin[61,62]. Mokkala *et al*[63] indicated that GlycA reflects gut microbiome diversity and is more accurate than hsCRP in reflecting metabolomic profile. Thus, proinflammatory factors, IGFBP and GlycA can be added as indicators to observe IR.

Administration of specific probiotics from the second and third trimester of pregnancy can enrich the diversity of gut microbiota in obese pregnant women, but the effect on reducing fasting blood glucose in overweight/obese pregnant women is still controversial and no positive findings on preventing the incidence of GDM were observed in these trials. As a result of strain specificity, different strains, dose, method, and duration of diverse probiotic species, as well as the influence of combining dietary counseling on their interventional effects should be extensively studied in the future. We suggest that further studies should increase the sample size and study population, provide comprehensive details of the study design, and be conducted in more high-risk GDM groups.

Table 1 summarizes the effects of probiotics on GDM in studies conducted in overweight and obese pregnant women. GDM is diagnosed by the criteria of the International Association of The Diabetes and Pregnancy study Group in the table.

**EFFECTS OF PROBIOTICS ON OTHER MATERNAL AND INFANT OUTCOMES IN OVERWEIGHT/OBESE PREGNANT WOMEN**

Taking probiotics can modulate the diversity of gut microbiota in obese pregnant women, and may even affect infants’ gut microbiota, which may have a positive impact on their growth and health[11,64]. The previous research mentioned noted that probiotics may reduce GWG, the mean neonatal total serum bilirubin (TSB) on days 3-5 after birth and small for gestation age (SGA) infants in overweight/obese pregnant women, while other outcomes were not significantly different.

***Maternal outcomes***

Other maternal outcomes besides glucose metabolism include GWG, pre-eclampsia, hypertensive disorders of pregnancy, cesarean delivery, postpartum hemorrhage, and lipid metabolism (cholesterol content). In overweight/obese pregnant women, Callaway *et al*[51] showed lower rates of GWG in women in the probiotics group, but there were no differences in overall weight gain between the groups or weight gain per week. Maternal overweight/obesity and excessive GWG were associated with reduced diversity of gut microbiota[65]. Halkjær *et al*[41] conducted an intention-to-treat and per protocol analysis that showed a lower GWG during the intervention period and increased α-diversity of gut microbiota in the probiotic group compared with the placebo group, although this difference in GWG did not reach significance, possibly because of the small sample size. The administration of probiotics may reduce body weight, although the effect sizes are small[31,66,67]. However, the latest systematic reviews and meta-analyses in 2022 showed that there were no significant differences between probiotics and placebo on excess weight gain in overweight/obese pregnant women[9,10].

The administration of probiotics can reverse alterations or dysregulation of the gut microbiota[68] and decrease both the proportion of lipopolysaccharide-containing microbiota in the gut and plasma lipopolysaccharides. However, there is insufficient evidence to support the role of probiotics in improving blood lipid profile in overweight/obese pregnant women. Lindsay *et al*[55] observed no effect of probiotic intervention on the lipid concentration after administration of probiotics, while the total cholesterol, low density lipoprotein, and triglycerides were lower. Probiotics may be associated with a slight reduction in triglycerides and total cholesterol in treating women with GDM[4]. The increased risk of pre-eclampsia (high-quality evidence) and hypertensive disorders of pregnancy with probiotics reported by Davidson *et al*[8] should be noted. There were few differences between the groups in terms of other outcomes such as cesarean section rate and postpartum hemorrhage.

***Neonatal outcomes***

Neonatal outcomes in studies that provided probiotics to overweight/obese pregnant women, included macrosomia, SGA, prematurity, jaundice, admission to the neonatal intensive care unit (NICU), and neonatal death within 30 d after birth. Asgharian *et al*[6] analyzed the occurrence of jaundice, treatments used for jaundice and TSB measured on days 3-5 after birth in heel capillary blood, and found that the mean neonatal TSB on days 3-5 after birth and use of all types of treatment, including phototherapy (alone or with other treatments), were significantly lower in the probiotic group than in the conventional yoghurt group. This was the first study to explore neonatal bilirubin level following administration of probiotics in overweight/obese pregnant women. Two systematic reviews and meta-analyses showed that probiotics supplement therapy may be effective in treating neonatal jaundice, but the evidence is low certainty and quality[69,70]. Chen *et al*[70] demonstrated that probiotic supplementation is an effective and safe treatment for pathological neonatal jaundice. However, a meta-analysisin 2019 did not recommend routine use of probiotics to prevent or treat neonatal jaundice as limited low-quality evidence indicated that probiotic supplementation may reduce the duration of phototherapy in neonates with jaundice[69]. Large well-designed adequately-powered trials on probiotic supplementation during pregnancy in overweight/obese pregnant women are still needed to identify whether probiotics reduce the occurrence of neonatal jaundice and the mean neonatal TSB level on days 3-5 after birth, and improve the efficacy of phototherapy for jaundice, alone or combined with other treatments. Callaway *et al*[51] found that probiotics have a role in the prevention of SGA, but this requires further investigation in future meta-analyses. Other neonatal outcomes such as microsomia, premature admission to the NICU, and neonatal death were not significantly different between the two groups[3,7,41,51,55].

**CONCLUSION**

Overweight/obese pregnant women, excessive weight gain during pregnancy, and abnormal gut microbiota are high-risk factors for GDM, and probiotics may be more effective in high-risk pregnant women in preventing GDM by modulating the gut microbiota and inhibiting the expression of inflammatory factors. Current evidenceindicates that multiple probiotics may increase α-diversity in obese pregnant women, and probiotics have a positive effect on reducing fasting glucose and GWG in overweight/obese pregnant women and the incidence of SGA, as well as the mean neonatal TSB on days 3-5 after birth. However, probiotics have little effect on other maternal and neonatal outcomes such as GDM, preterm birth and macrosomia. At present, there have been no trials on probiotics in overweight/obese pregnant women in China. More, large, well-designed adequately powered trials are needed to identify the influence of probiotics on maternal and neonatal outcomes in overweight/obese pregnant women in different countries. We suggest the following: (1) Because of the specificity of species and strains of probiotics, future studies should identify the most appropriate probiotics to prevent GDM and other adverse maternal and neonatal outcomes in overweight/obese pregnant women, and enroll more participants at high risk of GDM; (2) Study design should be improved, for example, combining dietary counseling with probiotics intervention may be beneficial in reducing the incidence of GDM; and (3) Large multicenter studies and probiotics administration from early pregnancy should be implemented to determine the optimal dosage, method, and timing of probiotics use.

**REFERENCES**

1 **Hill C**, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 506-514 [PMID: 24912386 DOI: 10.1038/nrgastro.2014.66]

2 **Sheyholislami H**, Connor KL. Are Probiotics and Prebiotics Safe for Use during Pregnancy and Lactation? A Systematic Review and Meta-Analysis. *Nutrients* 2021; **13** [PMID: 34371892 DOI: 10.3390/nu13072382]

3 **Pellonperä O**, Mokkala K, Houttu N, Vahlberg T, Koivuniemi E, Tertti K, Rönnemaa T, Laitinen K. Efficacy of Fish Oil and/or Probiotic Intervention on the Incidence of Gestational Diabetes Mellitus in an At-Risk Group of Overweight and Obese Women: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. *Diabetes Care* 2019; **42**: 1009-1017 [PMID: 30967436 DOI: 10.2337/dc18-2591]

4 **Okesene-Gafa KA**, Moore AE, Jordan V, McCowan L, Crowther CA. Probiotic treatment for women with gestational diabetes to improve maternal and infant health and well-being. *Cochrane Database Syst Rev* 2020; **6**: CD012970 [PMID: 32575163 DOI: 10.1002/14651858.CD012970.pub2]

5 **Kijmanawat A**, Panburana P, Reutrakul S, Tangshewinsirikul C. Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial. *J Diabetes Investig* 2019; **10**: 163-170 [PMID: 29781243 DOI: 10.1111/jdi.12863]

6 **Asgharian H**, Homayouni-Rad A, Mirghafourvand M, Mohammad-Alizadeh-Charandabi S. Effect of probiotic yoghurt on plasma glucose in overweight and obese pregnant women: a randomized controlled clinical trial. *Eur J Nutr* 2020; **59**: 205-215 [PMID: 31069459 DOI: 10.1007/s00394-019-01900-1]

7 **Shahriari A**, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial. *Biomed Pharmacother* 2021; **141**: 111915 [PMID: 34328109 DOI: 10.1016/j.biopha.2021.111915]

8 **Davidson SJ**, Barrett HL, Price SA, Callaway LK, Dekker Nitert M. Probiotics for preventing gestational diabetes. *Cochrane Database Syst Rev* 2021; **4**: CD009951 [PMID: 33870484 DOI: 10.1002/14651858.CD009951.pub3]

9 **Chu X**, Yan P, Zhang N, Feng L, Li X, Wang Y, Yang K. Probiotics for preventing gestational diabetes mellitus in overweight or obese pregnant women: A systematic review and meta-analysis. *Clin Nutr ESPEN* 2022; **50**: 84-92 [PMID: 35871956 DOI: 10.1016/j.clnesp.2022.05.007]

10 **Xie E**, Tao H, Liu M, Li C, Zhao Q. The effect of exercise on the prevention of gestational hypertension in obese and overweight pregnant women: An updated meta-analysis. *Front Public Health* 2022; **10**: 923161 [PMID: 36045739 DOI: 10.3389/fpubh.2022.923161]

11 **Isolauri E**, Rautava S, Collado MC, Salminen S. Role of probiotics in reducing the risk of gestational diabetes. *Diabetes Obes Metab* 2015; **17**: 713-719 [PMID: 25885278 DOI: 10.1111/dom.12475]

12 **Schwabe RF**, Greten TF. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. *J Hepatol* 2020; **72**: 230-238 [PMID: 31954488 DOI: 10.1016/j.jhep.2019.08.016]

13 **Milani C**, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, Belzer C, Delgado Palacio S, Arboleya Montes S, Mancabelli L, Lugli GA, Rodriguez JM, Bode L, de Vos W, Gueimonde M, Margolles A, van Sinderen D, Ventura M. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. *Microbiol Mol Biol Rev* 2017; **81** [PMID: 29118049 DOI: 10.1128/MMBR.00036-17]

14 **Koren O**, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, Gonzalez A, Werner JJ, Angenent LT, Knight R, Bäckhed F, Isolauri E, Salminen S, Ley RE. Host remodeling of the gut microbiome and metabolic changes during pregnancy. *Cell* 2012; **150**: 470-480 [PMID: 22863002 DOI: 10.1016/j.cell.2012.07.008]

15 **Lv Y**, Yan Z, Zhao X, Gang X, He G, Sun L, Li Z, Wang G. The effects of gut microbiota on metabolic outcomes in pregnant women and their offspring. *Food Funct* 2018; **9**: 4537-4547 [PMID: 30101246 DOI: 10.1039/c8fo00601f]

16 **Huang L**, Cai M, Li L, Zhang X, Xu Y, Xiao J, Huang Q, Luo G, Zeng Z, Jin C, Jin Y, He J, Yang W. Gut microbiota changes in preeclampsia, abnormal placental growth and healthy pregnant women. *BMC Microbiol* 2021; **21**: 265 [PMID: 34607559 DOI: 10.1186/s12866-021-02327-7]

17 **American Diabetes Association**. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. *Diabetes Care* 2020; **43**: S14-S31 [PMID: 31862745 DOI: 10.2337/dc20-S002]

18 **Guo F**, Yang S, Zhang Y, Yang X, Zhang C, Fan J. Nomogram for prediction of gestational diabetes mellitus in urban, Chinese, pregnant women. *BMC Pregnancy Childbirth* 2020; **20**: 43 [PMID: 31959134 DOI: 10.1186/s12884-019-2703-y]

19 **Kim SY**, England L, Wilson HG, Bish C, Satten GA, Dietz P. Percentage of gestational diabetes mellitus attributable to overweight and obesity. *Am J Public Health* 2010; **100**: 1047-1052 [PMID: 20395581 DOI: 10.2105/AJPH.2009.172890]

20 **Gao C**, Sun X, Lu L, Liu F, Yuan J. Prevalence of gestational diabetes mellitus in mainland China: A systematic review and meta-analysis. *J Diabetes Investig* 2019; **10**: 154-162 [PMID: 29683557 DOI: 10.1111/jdi.12854]

21 **Simmons D**. Prevention of gestational diabetes mellitus: Where are we now? *Diabetes Obes Metab* 2015; **17**: 824-834 [PMID: 25974384 DOI: 10.1111/dom.12495]

22 Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. *World Health Organ Tech Rep Ser* 1995; **854**: 1-452 [PMID: 8594834]

23 **Li HY**, Zhou DD, Gan RY, Huang SY, Zhao CN, Shang A, Xu XY, Li HB. Effects and Mechanisms of Probiotics, Prebiotics, Synbiotics, and Postbiotics on Metabolic Diseases Targeting Gut Microbiota: A Narrative Review. *Nutrients* 2021; **13** [PMID: 34579087 DOI: 10.3390/nu13093211]

24 **US Preventive Services Task Force**. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2008; **148**: 759-765 [PMID: 18490688 DOI: 10.7326/0003-4819-148-10-200805200-00008]

25 **Barrett HL**, Dekker Nitert M, Conwell LS, Callaway LK. Probiotics for preventing gestational diabetes. *Cochrane Database Syst Rev* 2014; **2014**: CD009951 [PMID: 24574258 DOI: 10.1002/14651858.CD009951.pub2]

26 **Agha-Jaffar R**, Oliver N, Johnston D, Robinson S. Gestational diabetes mellitus: does an effective prevention strategy exist? *Nat Rev Endocrinol* 2016; **12**: 533-546 [PMID: 27339886 DOI: 10.1038/nrendo.2016.88]

27 **Peng TR**, Wu TW, Chao YC. Effect of Probiotics on the Glucose Levels of Pregnant Women: A Meta-Analysis of Randomized Controlled Trials. *Medicina (Kaunas)* 2018; **54** [PMID: 30388861 DOI: 10.3390/medicina54050077]

28 **Markowiak-Kopeć P**, Śliżewska K. The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. *Nutrients* 2020; **12** [PMID: 32316181 DOI: 10.3390/nu12041107]

29 **Szczuko M**, Kikut J, Maciejewska D, Kulpa D, Celewicz Z, Ziętek M. The Associations of SCFA with Anthropometric Parameters and Carbohydrate Metabolism in Pregnant Women. *Int J Mol Sci* 2020; **21** [PMID: 33287163 DOI: 10.3390/ijms21239212]

30 **Santacruz A**, Collado MC, García-Valdés L, Segura MT, Martín-Lagos JA, Anjos T, Martí-Romero M, Lopez RM, Florido J, Campoy C, Sanz Y. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. *Br J Nutr* 2010; **104**: 83-92 [PMID: 20205964 DOI: 10.1017/S0007114510000176]

31 **Abenavoli L**, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, Aiello V, Romano B, De Lorenzo A, Izzo AA, Capasso R. Gut Microbiota and Obesity: A Role for Probiotics. *Nutrients* 2019; **11** [PMID: 31703257 DOI: 10.3390/nu11112690]

32 **Hersoug LG**, Møller P, Loft S. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity. *Nutr Res Rev* 2018; **31**: 153-163 [PMID: 29362018 DOI: 10.1017/S0954422417000269]

33 **Torres-Fuentes C**, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. *Lancet Gastroenterol Hepatol* 2017; **2**: 747-756 [PMID: 28844808 DOI: 10.1016/S2468-1253(17)30147-4]

34 **Shirvani-Rad S**, Tabatabaei-Malazy O, Mohseni S, Hasani-Ranjbar S, Soroush AR, Hoseini-Tavassol Z, Ejtahed HS, Larijani B. Probiotics as a Complementary Therapy for Management of Obesity: A Systematic Review. *Evid Based Complement Alternat Med* 2021; **2021**: 6688450 [PMID: 33552218 DOI: 10.1155/2021/6688450]

35 **Rao AY**, Yang JY, Liu CH, Wang DM. Meta-Analysis for Relationship between Intestinal Flora and Gestational Diabetes Mellitus (GDM). *ACM* 2020; **10**: 2766-2778 [DOI: 10.12677/ACM.2020.1011422]

36 **Hasain Z**, Mokhtar NM, Kamaruddin NA, Mohamed Ismail NA, Razalli NH, Gnanou JV, Raja Ali RA. Gut Microbiota and Gestational Diabetes Mellitus: A Review of Host-Gut Microbiota Interactions and Their Therapeutic Potential. *Front Cell Infect Microbiol* 2020; **10**: 188 [PMID: 32500037 DOI: 10.3389/fcimb.2020.00188]

37 **Mokkala K**, Paulin N, Houttu N, Koivuniemi E, Pellonperä O, Khan S, Pietilä S, Tertti K, Elo LL, Laitinen K. Metagenomics analysis of gut microbiota in response to diet intervention and gestational diabetes in overweight and obese women: a randomised, double-blind, placebo-controlled clinical trial. *Gut* 2021; **70**: 309-318 [PMID: 32839200 DOI: 10.1136/gutjnl-2020-321643]

38 **Li FX**, Tian G, Niu XY, Yu T, Peng YH. Research progress on the relationship between gut microbiota and probiotics and gestational diabetes mellitus. *Chin J Clin Obstet Gynecol* 2019; **20**: 566-568 [DOI: 10.5005/jp/books/11909\_12]

39 **Obuchowska A**, Gorczyca K, Standyło A, Obuchowska K, Kimber-Trojnar Ż, Wierzchowska-Opoka M, Leszczyńska-Gorzelak B. Effects of Probiotic Supplementation during Pregnancy on the Future Maternal Risk of Metabolic Syndrome. *Int J Mol Sci* 2022; **23** [PMID: 35897822 DOI: 10.3390/ijms23158253]

40 **Houttu N**, Mokkala K, Saleem WT, Virtanen S, Juhila J, Koivuniemi E, Pellonperä O, Tertti K, Luokola P, Sorsa T, Salonen A, Lahti L, Laitinen K. Potential pathobionts in vaginal microbiota are affected by fish oil and/or probiotics intervention in overweight and obese pregnant women. *Biomed Pharmacother* 2022; **149**: 112841 [PMID: 35344737 DOI: 10.1016/j.biopha.2022.112841]

41 **Halkjær SI**, de Knegt VE, Lo B, Nilas L, Cortes D, Pedersen AE, Mirsepasi-Lauridsen HC, Andersen LO, Nielsen HV, Stensvold CR, Johannesen TB, Kallemose T, Krogfelt KA, Petersen AM. Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study. *Curr Dev Nutr* 2020; **4**: nzaa095 [PMID: 32617453 DOI: 10.1093/cdn/nzaa095]

42 **Pan YQ**, Zheng QX, Jiang XM, Chen XQ, Zhang XY, Wu JL. Probiotic Supplements Improve Blood Glucose and Insulin Resistance/Sensitivity among Healthy and GDM Pregnant Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Evid Based Complement Alternat Med* 2021; **2021**: 9830200 [PMID: 34603479 DOI: 10.1155/2021/9830200]

43 **Chatzakis C**, Goulis DG, Mareti E, Eleftheriades M, Zavlanos A, Dinas K, Sotiriadis A. Prevention of gestational diabetes mellitus in overweight or obese pregnant women: A network meta-analysis. *Diabetes Res Clin Pract* 2019; **158**: 107924 [PMID: 31738997 DOI: 10.1016/j.diabres.2019.107924]

44 **Sánchez B**, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. *Mol Nutr Food Res* 2017; **61** [PMID: 27500859 DOI: 10.1002/mnfr.201600240]

45 **Akbaba G**, Akbaba E, Sahin C, Kara M. The relationship between gestational diabetes mellitus and selenoprotein-P plasma 1 (SEPP1) gene polymorphisms. *Gynecol Endocrinol* 2018; **34**: 849-852 [PMID: 29648467 DOI: 10.1080/09513590.2018.1460659]

46 **Rivière A**, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Front Microbiol* 2016; **7**: 979 [PMID: 27446020 DOI: 10.3389/fmicb.2016.00979]

47 **Sanders ME**, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 605-616 [PMID: 31296969 DOI: 10.1038/s41575-019-0173-3]

48 **Liu X**, Mao B, Gu J, Wu J, Cui S, Wang G, Zhao J, Zhang H, Chen W. Blautia-a new functional genus with potential probiotic properties? *Gut Microbes* 2021; **13**: 1-21 [PMID: 33525961 DOI: 10.1080/19490976.2021.1875796]

49 **Szulińska M**, Łoniewski I, van Hemert S, Sobieska M, Bogdański P. Dose-Dependent Effects of Multispecies Probiotic Supplementation on the Lipopolysaccharide (LPS) Level and Cardiometabolic Profile in Obese Postmenopausal Women: A 12-Week Randomized Clinical Trial. *Nutrients* 2018; **10** [PMID: 29914095 DOI: 10.3390/nu10060773]

50 **Zheng J**, Feng Q, Zheng S, Xiao X. The effects of probiotics supplementation on metabolic health in pregnant women: An evidence based meta-analysis. *PLoS One* 2018; **13**: e0197771 [PMID: 29782556 DOI: 10.1371/journal.pone.0197771]

51 **Callaway LK**, McIntyre HD, Barrett HL, Foxcroft K, Tremellen A, Lingwood BE, Tobin JM, Wilkinson S, Kothari A, Morrison M, O'Rourke P, Pelecanos A, Dekker Nitert M. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial. *Diabetes Care* 2019; **42**: 364-371 [PMID: 30659070 DOI: 10.2337/dc18-2248]

52 **Gomez Arango LF**, Barrett HL, Callaway LK, Nitert MD. Probiotics and pregnancy. *Curr Diab Rep* 2015; **15**: 567 [PMID: 25398206 DOI: 10.1007/s11892-014-0567-0]

53 **Luoto R**, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. *Br J Nutr* 2010; **103**: 1792-1799 [PMID: 20128938 DOI: 10.1017/S0007114509993898]

54 **Okesene-Gafa KAM**, Li M, McKinlay CJD, Taylor RS, Rush EC, Wall CR, Wilson J, Murphy R, Taylor R, Thompson JMD, Crowther CA, McCowan LME. Effect of antenatal dietary interventions in maternal obesity on pregnancy weight-gain and birthweight: Healthy Mums and Babies (HUMBA) randomized trial. *Am J Obstet Gynecol* 2019; **221**: 152.e1-152.e13 [PMID: 30878323 DOI: 10.1016/j.ajog.2019.03.003]

55 **Lindsay KL**, Kennelly M, Culliton M, Smith T, Maguire OC, Shanahan F, Brennan L, McAuliffe FM. Probiotics in obese pregnancy do not reduce maternal fasting glucose: a double-blind, placebo-controlled, randomized trial (Probiotics in Pregnancy Study). *Am J Clin Nutr* 2014; **99**: 1432-1439 [PMID: 24646819 DOI: 10.3945/ajcn.113.079723]

56 **Homayoni Rad A**, Mehrabany EV, Alipoor B, Mehrabany LV, Javadi M. Do probiotics act more efficiently in foods than in supplements? *Nutrition* 2012; **28**: 733-736 [PMID: 22704699 DOI: 10.1016/j.nut.2012.01.012]

57 **Gibson GR**, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 491-502 [PMID: 28611480 DOI: 10.1038/nrgastro.2017.75]

58 **Cunningham M**, Azcarate-Peril MA, Barnard A, Benoit V, Grimaldi R, Guyonnet D, Holscher HD, Hunter K, Manurung S, Obis D, Petrova MI, Steinert RE, Swanson KS, van Sinderen D, Vulevic J, Gibson GR. Shaping the Future of Probiotics and Prebiotics. *Trends Microbiol* 2021; **29**: 667-685 [PMID: 33551269 DOI: 10.1016/j.tim.2021.01.003]

59 **Swanson KS**, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, Scott KP, Holscher HD, Azad MB, Delzenne NM, Sanders ME. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 687-701 [PMID: 32826966 DOI: 10.1038/s41575-020-0344-2]

60 **Houttu N**, Mokkala K, Koivuniemi E, Pellonperä O, Juhila J, Sorsa T, Laitinen K. The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial. *Biomolecules* 2020; **11** [PMID: 33375174 DOI: 10.3390/biom11010005]

61 **Otvos JD**, Shalaurova I, Wolak-Dinsmore J, Connelly MA, Mackey RH, Stein JH, Tracy RP. GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. *Clin Chem* 2015; **61**: 714-723 [PMID: 25779987 DOI: 10.1373/clinchem.2014.232918]

62 **Duprez DA**, Jacobs DR Jr. GlycA, a composite low-grade inflammatory marker, predicts mortality: prime time for utilization? *J Intern Med* 2019; **286**: 610-612 [PMID: 31309635 DOI: 10.1111/joim.12961]

63 **Mokkala K**, Houttu N, Koivuniemi E, Sørensen N, Nielsen HB, Laitinen K. GlycA, a novel marker for low grade inflammation, reflects gut microbiome diversity and is more accurate than high sensitive CRP in reflecting metabolomic profile. *Metabolomics* 2020; **16**: 76 [PMID: 32564244 DOI: 10.1007/s11306-020-01695-x]

64 **Saha S**, Saha S. The effects of prenatal dietary supplements on blood glucose and lipid metabolism in gestational diabetes mellitus patients: A systematic review and network meta-analysis protocol of randomized controlled trials. *PLoS One* 2022; **17**: e0267854 [PMID: 35503790 DOI: 10.1371/journal.pone.0267854]

65 **Grech A**, Collins CE, Holmes A, Lal R, Duncanson K, Taylor R, Gordon A. Maternal exposures and the infant gut microbiome: a systematic review with meta-analysis. *Gut Microbes* 2021; **13**: 1-30 [PMID: 33978558 DOI: 10.1080/19490976.2021.1897210]

66 **Borgeraas H**, Johnson LK, Skattebu J, Hertel JK, Hjelmesaeth J. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. *Obes Rev* 2018; **19**: 219-232 [PMID: 29047207 DOI: 10.1111/obr.12626]

67 **Cerdó T**, García-Santos JA, G Bermúdez M, Campoy C. The Role of Probiotics and Prebiotics in the Prevention and Treatment of Obesity. *Nutrients* 2019; **11** [PMID: 30875987 DOI: 10.3390/nu11030635]

68 **Salazar J**, Angarita L, Morillo V, Navarro C, Martínez MS, Chacín M, Torres W, Rajotia A, Rojas M, Cano C, Añez R, Rojas J, Bermudez V. Microbiota and Diabetes Mellitus: Role of Lipid Mediators. *Nutrients* 2020; **12** [PMID: 33023000 DOI: 10.3390/nu12103039]

69 **Deshmukh J**, Deshmukh M, Patole S. Probiotics for the management of neonatal hyperbilirubinemia: a systematic review of randomized controlled trials. *J Matern Fetal Neonatal Med* 2019; **32**: 154-163 [PMID: 28823200 DOI: 10.1080/14767058.2017.1369520]

70 **Chen Z**, Zhang L, Zeng L, Yang X, Jiang L, Gui G, Zhang Z. Probiotics Supplementation Therapy for Pathological Neonatal Jaundice: A Systematic Review and Meta-Analysis. *Front Pharmacol* 2017; **8**: 432 [PMID: 28713275 DOI: 10.3389/fphar.2017.00432]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** September 17, 2022

**First decision:** October 30, 2022

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Serban ED, Romania; Sivashanmugam K, India **S-Editor:** Wang JJ **L-Editor:** Filipodia **P-Editor:**

**Table 1 Use of probiotics in the prevention of gestational diabetes and infant outcomes in overweight and obese pregnant women**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Participant** | **Strain** | **Dosage** | **Administration method** | **Administration duration** | **Sample size** | **Results** |
| Lindsay *et al*[55], 2014 | BMI 30.0-39.9 kg/m2 | *Lactobacillus salivarius* UCC118 | 109 CFU/d | Probiotic or placebo capsules refrigerated after a meal | 24-28 wk gestation | 175 (IG: 63; CG: 75) | FPG (probiotic: 4.60 mmol/L; placebo: 4.69 mmol/L, *P* = 0.391). Insulin (probiotic: 15.63 mU/L; placebo: 16.88 mU/L, *P* =0.16). HOMA2-IR (probiotic: 3.26; placebo: 3.53, *P* = 0.16). C-peptide (probiotic: 3.32 ng/mL; placebo: 3.37 ng/mL, *P* = 0.184). Total cholesterol (probiotic: 6.33 mmol/L; placebo: 6.60 mmol/L, *P* = 0.571). Total GWG (probiotic: 11.1 ± 6.2 kg *vs* placebo: 9.4 ± 5.6 kg, *P* = 0.479). PE (probiotic: 4.8%; placebo: 2.7%, *P* = 0.09) |
| Asgharian *et al*[6], 2020 | Pre- or early-pregnancy BMI ≥ 25 kg/m2 | *Lactobacillus acidophilus* La5 and *Bifidobacterium lactis* Bb12 | 100 g/d (5 × 108 CFU/g) | Probiotic or conventional yoghurt refrigerated | 24 wk of gestation until delivery | 130 (IG: 64; CG: 64) | FPG (probiotic yoghurt: 74.8 mg/dL; conventional yoghurt: 77.9 mg/dL, *P* = 0.008). 1 h OGTT (probiotic yoghurt: 128.0 mg/dL; conventional yoghurt: 136.0 mg/dL, *P* = 0.071). 2 h OGTT (probiotic yoghurt: 103.9 mg/dL; conventional yoghurt: 115.5 mg/dL, *P* = 0.002). GDM (probiotic yoghurt: 9%; conventional yoghurt: 17%, *P* = 0.184). Preeclampsia (probiotic yoghurt: 2%; conventional yoghurt: 0, *P* = 0.997). Preterm birth (probiotic yoghurt: 5%; conventional yoghurt: 13%, *P* = 0.077). Cesarean delivery (probiotic yoghurt: 52%; conventional yoghurt: 35%, *P* = 0.695). Total bilirubin on days 3-5 after birth (probiotic yoghurt: 9.1 mg/dL; conventional yoghurt: 11.3 mg/dL, *P* < 0.001). Treatment for hyperbilirubinemia (probiotic yoghurt: 36%; conventional yoghurt: 59%, *P* = 0.001). Phototherapy for hyperbilirubinemia (probiotic yoghurt: 16%; conventional yoghurt: 42%, *P* = 0.001) |
| Callaway *et al*[51], 2019 | BMI > 25 kg/m2 | *Lactobacillus rhamnosus* (LGG) and *Biﬁdobacterium animalis* subsp. *lactis*(BB-12) | 109 CFU/d | Probiotic or placebo capsules | Recruitment (12-20 wk of gestation) until birth | 433 (IG: 207; CG: 204) | GDM (probiotic: 18.4%; placebo: 12.3%, *P* = 0.184). FPG (probiotic: 79.3 mg/dL; placebo: 77.5 mg/dL, *P* = 0.049). PE (probiotic: 9.2%; placebo: 4.9%, *P* = 0.09). 28 wk diastolic BP (probiotic: 66.4 mmHg; placebo: 65 mmHg, *P* = 0.070). Excess weight gain (probiotic: 32.5%; placebo: 46%, *P* = 0.01). SAG < 10th percentile (probiotic: 2.4%; placebo: 6.5%, *P* = 0.042) |
| Pellonperä *et al*[3], 2019 | BMI ≥ 25 kg/m2 | *Lactobacillus rhamnosus* HN001 and *Biﬁdobacterium animalis* subsp. *lactis* 420 | 1010 CFU/d | Probiotic or placebo capsules refrigerated | 13.9 ± 2.1 wk of gestation until 6 mo postpartum | 439 (fish oil + placebo: 109; probiotics + placebo: 110; fish oil + probiotics: 109; placebo + placebo: 110) | -GDM (fish oil + placebo: 32.5%; probiotics + placebo: 28.4%; fish oil + probiotics: 36.9%; placebo + placebo: 36.9%, *P* = 0.59). Insulin (fish oil + placebo: 8.0 mU/L; probiotics + placebo: 5.5 mU/L; fish oil + probiotics: 6.6 mU/L; placebo + placebo: 6.4 mU/L, *P* = 0.16). HOMA2-IR (fish oil + placebo: 0.98; probiotics + placebo: 0.65; fish oil + probiotics: 0.80; placebo + placebo: 0.75, *P* = 0.12). SAG < 10th percentile (fish oil + placebo: 7.6%; probiotics + placebo: 7.3%; fish oil + probiotics: 8.7%; placebo + placebo: 9.8%, *P* = 0.93) |
| Okesene-Gafa *et al*[4], 2020 | BMI ≥ 30 kg/m2 | *Lactobacillus rhamnosus* GG and *Biﬁdobacterium lactis* BB12 | 6.5 × 109 CFU | Probiotic or placebo capsules | Recruitment (12-17 wk) until birth | 230 (IG: 115; CG: 115) | Excess weight gain (probiotic: 82.4%; conventional: 73.4%, *P* = 0.08). GDM (probiotic: 26.7% *vs* placebo: 27.5%, *P* = 0.80). Birthweight (probiotic: 3684 g *vs* placebo: 3504 g, *P* = 0.08) |
| Halkjær *et al*[41], 2020 | BMI ≥ 30 and < 35 kg/m2 | Probiotic mixture Vivomixx® (*Streptococcus thermophilus* DSM 24731, bifidobacteria and lactobacilli) | 450 × 109 CFU/d | Probiotic or placebo capsules refrigerated | 14-20 wk of gestation until delivery | 50 (IG: 25; CG: 24) | Total GWG (probiotic: 12.7 ± 5.3 kg *vs* placebo: 13.1 ± 5.8 kg, *P* = 0.82). Intervention period weight gain (probiotic: 10.2 ± 3.4 *vs* placebo: 10.0 ± 4.2, *P* = 0.87). Birthweight (probiotic: 3608 g *vs* placebo: 3640 g, *P* = 0.82). GDM (probiotic: 16% *vs* placebo: 8%, *P* = 0.67) |
| Shahriar *et al*[7], 2021 | High-risk pregnant women for GDM including BMI > 25 kg/m2 | Mixture of *Lactobacillus acidophilus* LA1, *Bifidobacterium longum* sp54 cs, and *Bifidobacterium bifidum* sp9 cs | 500 mg/d, 9.6 × 109 CFU | Probiotic or placebo capsules with a glass of water or milk (acidic or hot drinks were avoided) | 14 wk of pregnancy up to 24 wk | 542 (IG: 241; CG: 266) | GDM (probiotic: 41.9% *vs* placebo: 40.2%, *P* = 0.780). PE (probiotic: 17.8%; placebo: 17.3%, *P* = 0.87) |

BMI: Body mass index; CFU: Colony forming unit; CG: Control group; FPG: Fasting plasma glucose; GDM: Gestational diabetes mellitus; GWG: Gestational weight gain; HOMA-IR: Homeostasis model assessment of insulin resistance; IG: Intervention group; OGTT: Oral glucose tolerance test; PE: Preeclampsia; SGA: Small for gestation age.